RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 9, 2008, Pages 1448-1458

  Xue, Wan Jiang ^a,b   Li, Chun ^c   Zhou, Xiao Jun ^a   Guan, Hong Geng ^a   Qin, Lei ^a   Li, Peng ^b   Wang, Zhi Wei ^b   Qian, Hai Xin ^a  

^a SOOCHOW UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cyclin D1; Hepatocarcinogenesis; Mitomycin; Tumor suppressor

Indexed keywords

CYCLIN D1; HEPATITIS B SURFACE ANTIGEN; MITOMYCIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DNA CONTENT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 49849099834     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05067.x     Document Type: Article

References (39)

1. Chen JG, Yao HY, Zhu J, Zhang YH. Epidemic tendency analysis of hepatocellular carcinoma in Qidong County from 1969 to 2003. Chin. Med. Res. 2002 2 : 684 6.
2. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999 353 : 1253 7.
3. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997 25 : 259 62.
4. Mazzaferro V, Regalia E, Doci R et al. Liver Transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996 334 : 693 700.
5. Trinchet JC, Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis. J. Hepatol. 1997 27 : 756 65.
6. Bishop JM. The molecular genetics of cancer. Science 1987 235 : 305 11.
7. Tada M, Omata M, Ohto M. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res. 1990 50 : 1121 4.
8. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 2002 31 : 339 46.
9. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nat. Genet. 2000 25 : 315 19.
10. Kuzmin I, Gillespie JW, Protopopov A et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res. 2002 62 : 3498 502.
11. Dreijerink K, Braga E, Kuzmin I et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc. Natl. Acad. Sci. USA 2001 98 : 7504 9.
12. Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res. 2001 61 : 7034 8.
13. Lee MG, Kim HY, Byun DS et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res. 2001 61 : 6688 92.
14. Wong N, Li L, Tsang K, Lai PB, To KF, Johnson PJ. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J. Hepatol. 2002 37 : 633 9.
15. Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol. Cell. Biol. 2002 22 : 4309 18.
16. Ortiz-Vega S, Khokhlatchev A, Nedwidek M et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002 21 : 1381 90.
17. Lin S, Wang W, Wilson GM et al. Down-regulation of cyclin D1 expression by prostaglandin A2 is mediated by enhanced cyclin D1 mRNA turnover. Mol. Cell. Biol. 2000 20 : 7903 13.
18. Zhong S, Yeo W, Tang MW et al. Intensive hypermethylation of the CpG island of Ras association domain family 1A in Hepatitis B Virus-associated hepatocellular carcinomas. Clin. Cancer Res. 2003 9 : 3376 82.
19. Schagdarsurengin U, Wilkens L, Steinemann D et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003 22 : 1866 71.
20. Sun L, Hui AM, Kanai Y, Sakamoto M, Hirohashi S. Increased DNA methyltransferase expression is associated with an early stage of human hepatocarcinogenesis. Jpn. J. Cancer Res. 1997 88 : 1165 70.
21. Shen LL, Ahuja N, Shen Y et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. Cancer Inst. 2002 94 : 755 61.
22. McLean M, Dutton MF. Cellular interactions and metabolism of aflatoxin: an update. Pharmacol. Ther. 1995 65 : 163 92.
23. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 54 : 4855 78.
24. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991 350 : 427 8.
25. Zhang YJ, Ahsan H, Chen Y et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol. Carcinog. 2002 35 : 85 92.
26. Shen HM, Ong CN, Lee BL, Shi CY. Aflatoxin B-induced 8- hydroxydeoxyguanosine formations in rat hepatic DNA. Carcinogenesis 1995 16 : 419 22.
27. Weyden L, Tachiban KK, Gonzalez MA et al. The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol. Cell. Biol. 2005 25 : 8356 67.
28. Dallol A, Agathanggelou A, Tommasi S, Pfeifer GP, Maher ER, Latif F. Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. Cancer Res. 2005 65 : 7653 9.
29. Kondoh N, Wakatsuki T, Hada A et al. Genetic and epigenetic events in human hepatocarcinogenesis. Int. J. Oncol. 2001 18 : 1271 8.
30. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993 7 : 812 21.
31. Muller H, Lukas J, Schneider A et al. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc. Natl. Acad. Sci. USA 1994 91 : 2945 9.
32. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 1997 11 : 957 72.
33. Dufourny B, van Teeffelen HA, Hamelers IH, Sussenbach JS, Steenbergh PH. Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells. J. Endocrinol. 2000 166 : 329 38.
34. Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J. Biol. Chem. 2000 275 : 35669 72.
35. Bunz F, Hwang PM, Torrance C et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 1999 104 : 263 9.
36. Zhang Q, Ni Q, Gan J et al. p14ARF upregulation of p53 and enhanced effects of 5-fluorouracil in pancreatic cancer. Chin. Med. J. (Engl.). 2003 116 : 1150 5.
37. waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. Cancer Res. 1997 57 : 2193 9.
38. Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. J. Clin. Invest. 1999 104 : 1655 61.
39. Rabizadeh S, Xavier RJ, Ishiguro K et al. The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J. Biol. Chem. 2004 279 : 29247 54.